Jari P Lappalainen
Overview
Explore the profile of Jari P Lappalainen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
213
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ruotsalainen A, Lappalainen J, Heiskanen E, Merentie M, Sihvola V, Napankangas J, et al.
Cardiovasc Res
. 2018 Jun;
115(1):243-254.
PMID: 29917052
Aims: Oxidative stress and inflammation play an important role in the progression of atherosclerosis. Transcription factor NF-E2-related factor 2 (Nrf2) has antioxidant and anti-inflammatory effects in the vessel wall, but...
2.
Wennink J, Liu Y, Makinen P, Setaro F, de la Escosura A, Bourajjaj M, et al.
Eur J Pharm Sci
. 2017 Jul;
107:112-125.
PMID: 28679107
Selective elimination of macrophages by photodynamic therapy (PDT) is a new and promising therapeutic modality for the reduction of atherosclerotic plaques. m-Tetra(hydroxyphenyl)chlorin (mTHPC, or Temoporfin) may be suitable as photosensitizer...
3.
Laakkonen J, Lappalainen J, Theelen T, Toivanen P, Nieminen T, Jauhiainen S, et al.
Angiogenesis
. 2016 Nov;
20(1):109-124.
PMID: 27873103
Aims: Histamine and vascular endothelial growth factor A (VEGF) are central regulators in vascular pathologies. Their gene regulation leading to vascular remodeling has remained obscure. In this study, EC regulation...
4.
van Lith S, Roodink I, Verhoeff J, Makinen P, Lappalainen J, Yla-Herttuala S, et al.
Oncotarget
. 2016 Oct;
7(44):71594-71607.
PMID: 27689404
Diffuse gliomas are primary brain cancers that are characterised by infiltrative growth. Whereas high-grade glioma characteristically presents with perinecrotic neovascularisation, large tumor areas thrive on pre-existent vasculature as well. Clinical...
5.
Theelen T, Lappalainen J, Sluimer J, Gurzeler E, Cleutjens J, Gijbels M, et al.
Atherosclerosis
. 2015 Jun;
241(2):297-304.
PMID: 26062989
Objective: Angiopoietin-2 (Ang-2) blocking agents are currently undergoing clinical trials for use in cancer treatment. Ang-2 has also been associated with rupture-prone atherosclerotic plaques in humans, suggesting a role for...
6.
Ruotsalainen A, Inkala M, Partanen M, Lappalainen J, Kansanen E, Makinen P, et al.
Cardiovasc Res
. 2013 Jan;
98(1):107-15.
PMID: 23341579
Aims: The loss of nuclear factor E2-related factor 2 (Nrf2) has been shown to protect against atherogenesis in apoE-deficient mice. The mechanism by which Nrf2 deficiency affords atheroprotection in this...
7.
Leinonen H, Ruotsalainen A, Maatta A, Laitinen H, Kuosmanen S, Kansanen E, et al.
Cancer Res
. 2012 Oct;
72(23):6227-35.
PMID: 23041549
Nuclear factor erythroid-2 related factor 2 (Nrf2) is a transcription factor that regulates protection against a wide variety of toxic insults to cells, including cytotoxic cancer chemotherapeutic drugs. Many lung...
8.
Makinen P, Lappalainen J, Heinonen S, Leppanen P, Lahteenvuo M, Aarnio J, et al.
Cardiovasc Res
. 2010 Jul;
88(3):530-8.
PMID: 20634212
Aims: Macrophage scavenger receptor A (SR-A) and class B scavenger receptor CD36 (CD36) contribute to foam cell formation and atherogenesis via uptake of modified lipoproteins. So far, the role of...